Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin twice-daily versus once-daily add-on to metformin in type 2 diabetes
2012-000905-53Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline. Started Jun 2012; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-000905-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000905-53.